Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Farhad Lotfi, Fatemeh Khodabandeh, Abdosaleh Jafari, Mehdi Rezaee, Hamed Rahimi, Zahra Shiravani & Khosro Keshavarz. (2023) Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective. Expert Review of Pharmacoeconomics & Outcomes Research 23:4, pages 439-447.
Read now
Read now
Natalie Klag, Adam C Walter, Kristen M Sheely, Kelly J Manahan & John P Geisler. (2016) Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable?. ClinicoEconomics and Outcomes Research 8, pages 287-291.
Read now
Read now
S. Rachel Skinner, Dan Apter, Newton De Carvalho, Diane M. Harper, Ryo Konno, Jorma Paavonen, Barbara Romanowski, Cecilia Roteli-Martins, Nansa Burlet, Attila Mihalyi & Frank Struyf. (2016) Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Review of Vaccines 15:3, pages 367-387.
Read now
Read now
Jean-Jacques Body, Pierre Chevalier, Oliver Gunther, Guy Hechmati & Mark Lamotte. (2013) The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium. Journal of Medical Economics 16:4, pages 539-546.
Read now
Read now
Fredrik Herse & Eeva Reissell. (2011) The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland. Scandinavian Journal of Infectious Diseases 43:3, pages 209-215.
Read now
Read now
Articles from other publishers (24)
Caroline Dombrowski, Claire Bourgain, Yixuan Ma, Anne Meiwald, Amy Pinsent, Birgit Weynand, Katy M.E. Turner, Susie Huntington, Elisabeth J. Adams, Johannes Bogers, Romaric Croes & Shaira Sahebali. (2023) An economic evaluation of two cervical screening algorithms in Belgium: HR-HPV primary compared to HR-HPV and liquid-based cytology co-testing. European Journal of Cancer Prevention.
Crossref
Crossref
Hristina Lebanova, Svetoslav Stoev, Emilia Naseva, Violeta Getova, Wei Wang, Ugne Sabale & Elina Petrova. (2023) Economic Burden of Cervical Cancer in Bulgaria. International Journal of Environmental Research and Public Health 20:3, pages 2746.
Crossref
Crossref
Laurence Geebelen, Brecht Devleesschauwer, Tinne Lernout, Katrien Tersago, Yves Parmentier, Herman Van Oyen, Niko Speybroeck & Philippe Beutels. (2022) Lyme borreliosis in Belgium: a cost-of-illness analysis. BMC Public Health 22:1.
Crossref
Crossref
Steven Simoens, Andre Bento-Abreu, Barbara Merckx, Sophie Joubert, Steve Vermeersch, Andrew Pavelyev, Stefan Varga & Edith Morais. (2021) Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium. Frontiers in Pharmacology 12.
Crossref
Crossref
Mansoureh Refaei, Soodabeh Aghababaei & Mansoureh Yazdkhasti. (2020) Socioeconomic Consequences of Cervical Cancer: A Narrative Review. Current Womens Health Reviews 16:3, pages 194-200.
Crossref
Crossref
Koh Jun Ong, Marta Checchi, Lorna Burns, Charlotte Pavitt, Maarten J Postma & Mark Jit. (2019) Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Sexually Transmitted Infections 95:1, pages 28-35.
Crossref
Crossref
Mohsen Yaghoubi, Marzieh Nojomi, Atefeh Vaezi, Vida Erfani, Susan Mahmoudi, Khadijeh Ezoji, Seyed Mohsen Zahraei, Irtaza Chaudhri & Maziar Moradi-Lakeh. (2018) Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran. Value in Health Regional Issues 15, pages 112-119.
Crossref
Crossref
Mireia Diaz, David Moriña, Vanesa Rodríguez-Salés, Raquel Ibáñez, Josep Alfons Espinás & Silvia de Sanjosé. (2018) Moving towards an organized cervical cancer screening: costs and impact. European Journal of Public Health.
Crossref
Crossref
Christiaan H. Righolt, Gurpreet Pabla & Salaheddin M. Mahmud. (2018) The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada. Applied Health Economics and Health Policy 16:2, pages 195-205.
Crossref
Crossref
Taek Sang Lee, Smita Kothari-Talwar, Puneet K Singhal, Karen Yee, Amit Kulkarni, Nuria Lara, Montserrat Roset, Anna R Giuliano, Suzanne M Garland & Woong Ju. (2017) A cross-sectional study estimating the burden of illness related to genital warts in South Korea. BMJ Open 7:6, pages e014217.
Crossref
Crossref
Themba G. Ginindza, Benn Sartorius, Xolisile Dlamini & Ellinor ?stensson. (2017) Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. PLOS ONE 12:5, pages e0177762.
Crossref
Crossref
Elizabeth Thurgar, Samantha Barton, Charlotta Karner & Steven J Edwards. (2016) Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation. Health Technology Assessment 20:24, pages 1-486.
Crossref
Crossref
Ellinor ?stensson, Maria Fr?berg, Amy Leval, Ann-Cathrin Hellstr?m, Magnus B?cklund, Niklas Zethraeus & Sonia Andersson. (2015) Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination. PLOS ONE 10:9, pages e0139062.
Crossref
Crossref
Geraldine Dominiak-Felden, Corrado Gobbo & Fran?ois Simondon. (2015) Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study. PLOS ONE 10:7, pages e0132404.
Crossref
Crossref
Hillegonda Maria Dutilh Novaes, Alexander Itria, Gulnar Azevedo e Silva, Ana Marli Christovam Sartori, Cristina Helena Rama & Patrícia Coelho de Soárez. (2015) Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil. Clinics 70:4, pages 289-295.
Crossref
Crossref
Georges Van Kriekinge, Xavier Castellsagu?David Cibula & Nadia Demarteau. (2014) Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine 32:6, pages 733-739.
Crossref
Crossref
A.V. Kuznetsov, R.A. Müller, T. Ruzicka, T. Herzinger & L. Kuznetsov. (2013) Knowledge of sexually transmitted HPV infection, genitoanal warts, cancer and their prevention among young females after vaccine introduction in Germany. Journal of the European Academy of Dermatology and Venereology 27:12, pages 1527-1534.
Crossref
Crossref
Nadia Demarteau, Georges Van Kriekinge & Philippe Simon. (2013) Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Vaccine 31:37, pages 3962-3971.
Crossref
Crossref
Jeffrey Jen Hui Low, Yu Ko, Arunachalam Ilancheran, Xu Hao Zhang, Puneet K. Singhal & Sun Kuie Tay. (2012) Health and Economic Burden of HPV-related Diseases in Singapore. Asian Pacific Journal of Cancer Prevention 13:1, pages 305-308.
Crossref
Crossref
Adam J.N. Raymakers, Mohsen Sadatsafavi, Fawziah Marra & Carlo A. Marra. (2012) Economic and Humanistic Burden of External Genital Warts. PharmacoEconomics 30:1, pages 1-16.
Crossref
Crossref
Francesco Saverio Mennini, Alessandro Capone & Giampiero Favato. (2011) The use of an “old-fashioned method” to assess the clinical and economic impact of a HPV vaccination program. Gynecologic Oncology 123:1, pages 175-176.
Crossref
Crossref
I. Borget, L. Abramowitz & P. Mathevet. (2011) Economic burden of HPV-related cancers in France. Vaccine 29:32, pages 5245-5249.
Crossref
Crossref
S. Capri, R. Gasparini, D. Panatto & N. Demarteau. (2011) Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecologic Oncology 121:3, pages 514-521.
Crossref
Crossref
Lieven Annemans, Vanessa R?my, James Oyee & Nathalie Largeron. (2009) Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium. PharmacoEconomics 27:3, pages 231-245.
Crossref
Crossref